

March 18, 2014

## Astellas Pharma Inc. – Ratio Change and Stock Distribution

DR CUSIP: 04623U102  
DR ISIN: US04623U1025  
DR Ticker Symbol: ALPMY

Please be advised that Astellas Pharma Inc. has announced a 5 for 1 stock split on its ordinary shares in the local market effective April 1, 2014. As a result, BNY Mellon will change the ratio on the Astellas Pharma Inc. ADR program. The ratio change will occur simultaneously with a 25% DS distribution (0.25 additional DSs for each 1 DS held).

Please note the following:

DR Record Date: March 31, 2014  
DR Payable Date: April 1, 2014  
DR Distribution Rate: 25% Distribution (0.25 additional DSs for each 1 DS held)  
Old DR Ratio: 4 DR : 1 Common share  
**New DR Ratio: 1 DR : 1 Common share**  
Effective date for DR ratio change: April 2, 2014

An issuance fee of \$0.05 will be assessed.

**Please note: A ratio change may impact the fees payable by DR investors.**

BNY Mellon's books will be closed for all issuance and cancellation transactions from the close of business March 31, 2014 and will reopen on April 7, 2014.

---

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

<i><b>New York</b></i>	<i><b>London</b></i>	<i><b>Hong Kong</b></i>
Melissa Sobolewski/Ravi Davis	Damon Rowan	Herston Powers
+1 212 815-2267	Vice President	Vice President
Adrdesk@bnymellon.com	+44 207 964 6527	+852 2 840 9868
	damon.rowan@bnymellon.com	herston.powers@bnymellon.com

BNY Mellon may pay a rebate to brokers in connection with the deposit of shares for the issuance of unsponsored DRs; broker may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also transact with affiliate brokers and dealers. This information and data is provided for general purposes only; it is not investment advice and should not be used for any investment decisions nor trading purposes. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this announcement and shall have no liability for investment or other decisions based hereon, including market values loss on the sales or purchase of securities or other instruments or obligations. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.